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Risk of Cancer in Relatives of Prostate 
Cancer Probands
Sarah D. Isaacs, Lambertus A. L. M. Kiemeney, Agnes 
Baffoe-Bonnie, Terri H. Beaty, Patrick C. Walsh*
Background: It is estimated that there will be more than 244 000 
new prostate cancer cases diagnosed and that more than 40 000 
men will die of this disease during 1995. Evidence exists for a 
hereditary predisposition to prostate cancer, but the propor­
tion of cases attributable to the inheritance of a specific gene 
or genes is not large. Some hereditary cancer syndromes in­
volve more than one tumor site, and some studies have 
reported a familial association between prostate cancer and 
other cancers. The presence of other cancers in prostate can­
cer families may indicate a specific type of hereditary 
predisposition. Purpose: We studied families that were 
selected because of the presence of prostate cancer to deter­
mine whether hereditary prostate cancer is associated with 
cancers at other sites and possibly with other heritable can­
cer syndromes. Methods: Data from two distinct study 
populations were studied retrospectively. The first popula­
tion consisted of 690 case patients undergoing radical pros­
tatectomy who were not selected for family history of 
prostate cancer and 640 control subjects who were the 
spouses or female companions of the case patients. The 
second population consisted of 75 multiplex families (i.e., 
families with multiple cases of prostate cancer) referred be­
cause they fulfilled the criteria for hereditary prostate can­
cer. A comparison between case and control populations for 
the occurrence of 14 aggregated groups of cancer was per­
formed. Data were analyzed using Poisson regression, and 
relative risks (RRs) and their 95% confidence intervals (CIs) 
were calculated. Results: Brothers and fathers of prostate 
cancer probands have a statistically significant higher risk 
of prostate cancer than the male first-degree relatives of 
control subjects (RR = 1.76; 95% Cl = 1.28-2.43). Therefore, 
the risk for prostate cancer is 76% higher among first-de­
gree relatives of prostate cancer patients compared with 
first-degree relatives of control subjects. This higher risk 
was not modified by an occurrence of breast cancer in the 
pedigree. Also, a statistically significant higher risk was 
found for tumors of the central nervous system in hereditary 
families (RR = 3.02; 95% Cl = 1.08-8.41). Statistically sig­
nificant higher risks of cancer at other major sites, such as 
breast, ovary, or endometrium were not observed in these 
families. Conclusion: Even among families that were specifi­
cally selected because of the presence of prostate cancer, 
risks for cancer at other sites appeared not to be increased. 
Therefore, hereditary prostate cancer appears to be a rela­
tively site-specific disease, and it does not seem to be a part 
of other hereditary cancer syndromes. [J Natl Cancer Inst 
87:991-996,1995]
In recent years, much attention has been given to hereditary 
cancer syndromes, such as familial adenomatous polyposis, 
hereditary nonpolyposis colon cancer, hereditary breast-ovarian 
cancer, and Li-Fraumeni syndrome. It is known that some 
hereditary cancer syndromes are associated with more than one 
tumor site, whereas others are site specific. The involvement of 
other tumor sites in hereditary cancer syndromes may indicate 
that the genetic basis of cancer etiology in these families is 
heterogeneous (i.e., can be caused by more than one gene or 
subsets of genes).
Prostate cancer is the most prevalent malignancy among U.S. 
males. In 1995, there will be more than 244 000 new prostate 
cancer cases diagnosed and more than 40 000 deaths resulting 
from this disease (7). Evidence exists for a hereditary pre­
disposition to prostate cancer, but the proportion of all cases at­
tributable to a genetic cause is not large. To characterize familial 
prostate cancer, our group documented that a positive family 
history of prostate cancer is a useful index of individual risk 
(2,5) and that there is an increased risk for the development of 
prostate cancer both with an increasing number of affected rela­
tives and with earlier age at onset in the proband (i.e., identified 
case patient) (2,4). Using a test of various models to define this 
familial clustering, it is best explained by the autosomal domi­
nant inheritance of a rare, yet highly penetrant, gene that pre­
disposes men to the early development of prostate cancer (4). A 
working definition of hereditary prostate cancer has been pro­
posed to identify families at highest risk (5). Identification of the 
genes involved in families with hereditary prostate cancer 
should provide useful information to better understand the etiol­
ogy of this disease (5).
Previous case-control studies have provided evidence for an 
association between breast cancer and prostate cancer and pos­
sibly with endometrial and ovarian cancers. Macklin (6) gave 
evidence for a significantly higher frequency of prostate cancer 
among relatives of breast cancer patients than among relatives 
of control groups. She suggested that prostate cancer may be the 
male equivalent of some female breast cancers. Thiessen (7) 
reported a coaggregation of prostate cancer and uterine cancer
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in first-degree (mothers and sisters) and second-degree relatives 
of women with breast cancer. While Andrieu et al. (8) and 
Lynch et ah (9) did not find an association between prostate 
cancer and breast cancer, Anderson and Badzioch (10) reported 
that a family history of prostate cancer as well as endometrial 
and ovarian cancers significantly increased the risk of breast 
cancer.
Large cohort studies have also demonstrated a relationship 
between prostate and other cancers. One such study ( //)  made 
use of the Utah Mormon Genealogical Database in conjunction 
with the Utah Cancer Registry to test for familial aggregation 
involving 2821 cases of prostate cancer that occurred in Utah 
during the years 1958-1981. This study design was used to com­
pare all cancers and showed prostate cancer to have the fourth 
strongest degree of familial clustering after lip cancer, skin 
melanoma, and ovarian cancer. Prostate cancer had a higher de­
gree of familial aggregation than both colon and breast car­
cinomas, two solid tumors that are well recognized as having a 
genetic component. In this study, the ranking for prostate cancer 
and breast cancer coaggregation within the same pedigree was 
20th, whereas prostate cancer and uterine cancer coaggregation 
ranked 10th.
In a study of Icelandic women with breast cancer, Tulinius et 
a l (12) reported an increased risk of prostate cancer among all 
male relatives and in uncles, grandfathers, and cousins if the 
breast cancer proband had a father or brother with either breast 
cancer or prostate cancer. On the basis of a linkage analysis of 
seven multiplex families from this Icelandic study, however, 
Arason et al. (13) found no evidence of linkage to 17q (the loca­
tion of the BRCA1 gene) in five of the families.
In this article, we studied families that were selected because 
of the presence of prostate cancer to determine if hereditary 
prostate cancer could be associated with cancers at other sites 
and possibly with other heritable cancer syndromes.
Methods
Information from two distinct study populations was used. The first dataset 
was derived from a case-control study on familial prostate cancer. The second 
was from a collection of multiplex prostate cancer families (i.e., families with 
multiple cases of prostate cancer).
Case-Control Families
The study population and the method of data collection are described in detail 
elsewhere (2). The case families were ascertained through 741 consecutive 
probands undergoing radical prostatectomy for primary, clinically localized 
prostate cancer at The Johns Hopkins Hospital, Baltimore, MD, between 1982 
and 1989. Case patients were not selected for family history of disease. The con­
trol group consisted of the patients’ spouses or female companions. In 1989, 690 
(93%) probands were interviewed by telephone (17 patients were deceased, 26 
could not be located, seven refused to participate, and one turned out to be a 
duplicate).1 Six hundred forty (94%) of 683 control subjects completed the inter­
views (58 patients did not have spouses or female companions). The average age 
for case patients was 62.6 years (range, 34-76 years). This fairly young age dis­
tribution of a prostate cancer population is explained by the inclusion of patients 
who were candidates for radical prostateciomy only. The mean age of case 
patients with and without spousal or companion control subjects was the same. 
Ninety-six percent of the case patients were white.
Probands and control subjects were asked to recall cancer histories among 
siblings, children, parents, grandparents, aunts, and uncles. Only biological rela­
tives (i.e., no half siblings or relatives by marriage) were included. Positive 
family histories among first-degree relatives were investigated in a sample of the
reported cases and found to be accurate (2). Review of the family histories 
revealed that cancer occurrence among second-degree relatives was substantially 
underreported. Therefore, in the present analysis, only first-degree relatives are 
included. Prostate cancer occurrence in second-degree relatives was used, how­
ever, in an attempt to characterize hereditary prostate cancer; all probands in the 
case-control study were classified into one of three subgroups: hereditary, 
familial, and sporadic. The hereditary subgroup consisted of 31 (4.5% of total) 
families that met one of the following criteria: 1) a cluster of three or more rela­
tives affected with prostate cancer within any nuclear family, such as a father 
and two sons affected or a group of three brothers affected; 2) the occurrence of 
prostate cancer in each of three successive generations in either the proband’s 
paternal lineage or maternal lineage; or 3) a cluster of two relatives, both af­
fected with prostate cancer at 55 years of age or younger. These criteria were 
based on the results of a test of various models to explain familial clustering
(4j).
The familial subgroup consisted of 148 (21.5%) families in which there was a 
positive family history of prostate cancer, but the aforementioned conditions for 
inclusion in the hereditary subgroup were not met. Finally, the 511 (74%) 
simplex (i.e., single-case) families were defined as sporadic.
Multiplex Families
To increase the number of hereditary families, a letter was sent to 8000 
board-certified urologists in the United States, requesting referral of multiplex 
families to the study of Hereditary Prostate Cancer at Johns Hopkins. Names and 
addresses of patients with diagnosed prostate cancer were provided by the refer­
ring urologist. Subsequently, in 1993, the proband and living first-degree family 
members were contacted by telephone to obtain detailed information about fami­
ly history of all cancers. Also, each patient referral was sent a family cancer 
form to be filled out and returned to us. The form asked for the name, date of 
birth, relationship, vital status, cause of death, presence of cancer(s), type of can­
cels), and date(s) of diagnosis for each first-degree relative in the family. In this 
article, we report on the first 75 families contacted in this way. Each family met 
the hereditary prostate cancer criteria of at least three first-degree relatives diag­
nosed with prostate cancer (5).
Statistical Analysis
Cancer occurrence in first-degree relatives of case patients was compared 
with the occurrence of cancer in first-degree relatives of control subjects. In an 
additional analysis, the relatives of case patients were stratified according to the 
following subgroups: hereditary, familial, or sporadic. In the latter analysis only, 
the 31 hereditary families were enriched with the 75 multiplex families. Note 
that, under this study design, the offspring of case patients and control subjects 
are the same persons. First-degree relatives were therefore limited to parents and 
siblings of case patients or control subjects. For each of these relatives the num­
ber of person-years experienced was defined as the minimum of age at inter­
view, age at death, and age at diagnosis of first primary cancer. Second and 
subsequent primary cancers were not considered because the corresponding ages 
at diagnosis were not known. In the original interview, 37 types of cancer were 
reported. For this analysis, we reclassified these types into 14 groups: prostate, 
breast, colorectal, other digestive system (pancreas, stomach, liver, gallbladder, 
alimentary canal, abdominal, and intestinal), urinary tract (bladder and kidney), 
central nervous system (brain, spine, astrocytoma, and eye), head and neck 
(head/neck, esophagus, and thyroid), hematopoietic system (leukemia, lym­
phoma, and spleen), ovary, endometrium, other gynecologic system (cervix and 
female organ), respiratory system (lung and throat), skin (melanoma and skin), 
and other (testis, bone, hip/peivic area, back, ieg/knee area, unspecified, metas- 
tases, and other). This reclassification was done to reach higher statistical power 
and to avoid misclassification due to ill-defined tumor sites. The occurrence of 
these 14 aggregated groups of cancer in relatives of case patients and control 
subjects was assumed to follow a Poisson distribution. The Poisson distribution 
is a classic probability model used to describe the distribution of rare events, 
such as cancer incidence, as follows: piy) -  exp(-ji) where y = 0, 1 ,2 , . . . .
Because of the discrete and non-negative nature of count data, it can be as­
sumed that the logarithm of the expected count is a linear function of ex­
planatory variables, so that log E(y,) = x ’,(3. Here, the regression coefficient for a 
particular explanatory variable can be interpreted as the logarithm of the ratio of 
expected counts before and after a one-unit increase in that explanatory variable, 
with all other explanatory variables held constant. The assumption that Yf fol­
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lows a Poisson distribution implies that the variance and the mean of Y, are the 
same: Var(K.) = E(Y) -  expU',0) (14).
Data were analyzed by Poisson regression with EGRET (SERC, 1991) (15) 
and MULCOX2 (16) computer programs. Relative risks (RRs) and their 95% 
confidence intervals (CIs) were calculated (15), All P values are calculated from 
two-tailed tests of statistical significance.
Results
The 690 probands and 640 female companions in die case- 
control study had 3259 (of whom 1642 were males) and 3012 
(of whom 1518 were males) first-degree relatives, respectively. 
A total of 62 relatives were excluded from the study because of 
unknown age. The mean age of case patient relatives was 62.9 
years (±SD = 17.8 years). Case patient relatives experienced 
185 262 person-years when they were younger than 65 years of 
age and 19 638 person-years when they were 65 years of age 
and older. The mean age of the control subject relatives was 
slightly lower than that of the case patient relatives: 59.8 years 
(±SD =18.9 years). They experienced 165 913 and 15 214 per- 
son-years when they were younger than 65 years of age and 65 
years of age and older, respectively.
In Table 1» the RRs of cancer occurrence in case patient rela­
tives versus control subject relatives are summarized. Brothers 
and fathers of prostate cancer probands had a statistically sig­
nificant higher risk of prostate cancer than the first-degree male 
relatives of control subjects: RR = 1.76; 95% Cl = 1.28-2.43. 
The risks for cancer of the hematopoietic system (RR = 1.22; 
95% Cl = 0.75-1.99), urinary tract (RR = 1.22; 95% Cl = 0.66- 
2.26), and other sites (RR = 1.28; 95% Cl = 0.70-2.37) were 
slightly higher as well, but none of these higher risks was sig­
nificant. The risks for tumors of the central nervous system, 
head and neck region, ovary, endometrium, other gynecologic 
system, and respiratory system were lower than in the control
Table 1. Poisson regression relative risks (RRs) and 95% confidence intervals 
(CIs) of cancer occurrence in first-degree relatives of prostate cancer probands 
versus first-degree relatives of the prostate cancer probands ’ female companions
No. in No. in
proband control
Site relatives* relatives! RR (95% Cl)t
Prostate 119 55 1.76(1.28-2.43)
Breast 107 91 1.00 (0.76-1.33)
Colorectum 75 65 0.94 (0.67-1.31)
Other digestive system 95 74 1.07 (0.79-1.45)
Bladder or kidney 25 17 1.22 (0.66-2.26)
Central nervous system 14 14 0.82(0.39-1.73)
Head and neck 22 28 0.67 (0.39-1.18)
Hematopoietic system 39 27 1.22 (0.75-1.99)
Ovary 7 7 0.85 (0.30-2.44)
Endometrium 27 31 0.75 (0.45-1.26)
Other gynecologic system 10 20 0.44 (0.21-0.95)
Respiratory system 61 68 0.75 (0.53-1.06)
Skin melanoma 100 76 1.10(0.81-1.48)
Other 26 17 1.28 (0.70-2.37)
^Number of probands was 690; number of first-degree relatives was 3259; 
number of person-years experienced by male and female relatives of probands 
was 101 233 and 103 667, respectively.
tNumber of controls was 640; number of first-degree relatives was 3012; 
number of person-years experienced by male and female relatives of control sub­
jects was 89 036 and 91 091, respectively.
$ Adjusted for the effects of sex and age (>65 years versus <65 years).
subject relatives, but these decreased risks were not significant 
either, with the exception of the lower risk for other gynecologic 
tumors (RR -  0.44; 95% Cl = 0.21-0.95). With tests of interac­
tion between sex and case-control status, it appeared that the 
RR of other digestive system cancers differed for males and fe­
males. In males the RR = 0.69; 95% Cl = 0.44-1.07, whereas in 
females the RR = 1.60; 95% Cl = 1.04-2.47.
Of the 690 prostate cancer probands, 107 (15.5%) had at least 
one sister (n = 54), the mother (n = 49), or both a sister and the 
mother (n = 4) diagnosed with breast cancer. Table 2 presents 
the RRs of prostate cancer among first-degree relatives of pros­
tate cancer probands with and without a sister and/or mother 
with breast cancer. It appears that the higher risk of prostate 
cancer for brothers and fathers of probands (RR = 1.76; 95% Cl 
= 1.28-2.43) was only marginally modified if there was an addi­
tional breast cancer diagnosed in the nuclear family. Also, the 
higher risk was not modified by the age at which the breast can­
cer was diagnosed, i.e., before or after the age of 65 years. Only 
seven prostate cancer probands had a sister (n = 2) or mother (n 
= 5) with ovarian cancer. Among the 19 male family members 
of these probands, no prostate cancer was reported. Twenty- 
eight probands (4.1%) had a sister (n = 12), mother (n = 15), or 
both a sister and mother (n = 1) with endometrial cancer. Seven 
prostate cancers were reported among the 69 male relatives of 
these 28 probands (RR = 2.69; 95% Cl = 1.22-5.90). While this 
higher risk was statistically significant compared with the con­
trol subjects (P = .01), it was not significant when compared 
with other prostate cancer probands who did not have a case of 
endometrial cancer in the nuclear family (P = .26).
In 94 (13.6%) of the nuclear families of the prostate cancer 
probands, one additional male relative was affected with pros­
tate cancer (either a brother or the father). In 12 (1.7%) of the 
nuclear families, there were two or more affected nonprobands 
reported. The presence of prostate cancer in a male nonproband 
in the nuclear family appeared not to have any impact on the 
risk of breast cancer among female relatives (Table 3). Com­
pared with the control subject families, the RR of breast cancer 
for case patient families without prostate cancer in a nonproband 
was RR = 1.01; 95% Cl = 0.76-1.35. The RR for case patient 
families with prostate cancer in a nonproband was RR = 0.89; 
95% Cl = 0.49-1.63, and the RR for case patient families with at 
least two nonprobands with prostate cancer was RR = 1.37; 95% 
Cl =■ 0.34-5.55. The three corresponding RRs for endometrial 
cancer were RR = 0.68 (95% Cl -  0.39-1.18), RR = 1.11 (95% 
Cl = 0.43-2.85), and RR = 1.94 (95% Cl = 0.26-14.20), respec­
tively. The data were too sparse to do similar comparisons for 
ovarian cancer.
Risks for cancer of the breast and ovary were hardly 
modified by the age at diagnosis of the proband (Table 3). The 
RR of breast cancer for first-degree relatives of prostate cancer 
case patients diagnosed at 56 years of age or older was RR =
1.03; 95% Cl = 0.76-1.38. For the relatives of prostate cancer 
case patients diagnosed younger than 56 years of age, the RR 
appeared to be even lower: RR = 0.95; 95% Cl = 0.60-1.48. For 
ovarian cancer, these RRs were RR = 0.81; 95% Cl = 0.26-2.55 
and RR = 1.00; 95% Cl = 0.21-4.82, respectively. The risk of 
endometrial cancer for relatives of young prostate cancer pro­
bands appeared to be somewhat higher (RR = 1.34; 95% Cl =
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Table 2. Poisson regression relative risks (RRs) and 95% confidence intervals (CIs) of prostate cancer in first-degree relatives of prostate cancer probands with and
without a sister and/or mother with breast, ovarian, or endometrial cancer
Classification 
of relatives
All coiitroi subjects
All probands
Relatives of probands 
Without sister with breast cancer 
With sister with breast cancer 
Without mother with breast cancer 
With mother with breast cancer 
Without sister or mother 
with breast cancer 
With sister or mother 
with breast cancer 
Without sister or mother 
with breast cancer when 
younger than 55 years 
With sister or mother 
with breast cancer when 
younger than 55 years 
Without sister or mother 
with ovarian cancer 
With sister or mother 
with ovarian cancer 
Without sister or mother 
with endometrial cancer 
With sister or mother 
with endometrial cancer
No. of 
relatives
1518
1642
1481
161
1531
111
1380
262
1502
140
1623
19
1573
69
No. of 
person-years
89 036 
101 233
91 564 
9669
94 444 
6789 
85 401
15 832
92 871
8362
100 135
1098
97 076
4157
No. of 
prostate cancers
55
119
109 
10
110 
9
101
18
110
119
112
7
RR (95% Cl)*
1.76(1.28-2.43)
1.79(1.29-2.47) 
1.53(0.78-3.00) 
1.74(1.26-2.41) 
2.05 (1.01-4.14) 
1.77 (1.28-2.46)
1.70(1.00-2.90)
1.76 (1.27-2.43)
1.84 (0.91-3.72)
1.79 (1.30-2.46)
0
1.73 (1.25-2,38) 
2.69(1.22-5,90)
* Adjusted for age (>65 years versus <65 years),
0.69-2.62) than the risk for relatives of older probands (RR =
0.55; 95% Cl = 0.30-1.03).
In the second part of the analysis, the 690 families were 
grouped according to the family history of prostate cancer: 
sporadic, familial, and hereditary. The 31 hereditary families 
were combined with an additional 75 multiplex families for a 
total of 106 in this last group. The 75 multiplex families had 237 
first-degree relatives (offspring excluded) with cancer other than 
prostate cancer. Twenty-two of them had. an unknown age of 
diagnosis and were therefore excluded from the analysis. The 
remaining 215 relatives (77 males and 138 females) had a mean 
age of 65.3 years (±SD =16.1 years). Forty-two primary cancers 
were diagnosed among these relatives. The most prevalent sites 
were the breast (n = 9), lung (n = 9), and colorectum (n = 8).
There was no clear increasing trend in statistically significant 
higher risks for cancer at other major tumor sites, such as breast» 
ovary, or endometrium (Table 4). Most RRs fluctuate around the 
null value. However, a statistically significant higher risk was 
found for tumors of the central nervous system in hereditary 
cancer families (RR = 3.02; 95% Cl = 1.08-8.41) and for other 
sites in the familial (RR = 2.35; 95% Cl = 1.08-5.14) and 
hereditary groups (RR = 3.00; 95% Cl = 1.18-7.63).
Discussion
This study presents an exploratory analysis of the risk of 
other malignancies among relatives of prostate cancer probands 
and tests for possible modifying effects of such malignancies on
Table 3. Poisson regression relative risks (RRs) and 95% confidence intervals (CIs) of breast, ovarian, and endometrial cancer occurrence in first-degree relatives of
prostate cancer probands, stratified by age (>56 years versus <56 years) and by number of additional prostate cancer cases
Breast cancer Ovarian cancer Endometrial cancer
Group No. RR (95% Cl) No. RR (95% Cl) No. RR (95% Cl)
Control 91 7 31
Proband: age at diagnosis, y
>56 83 1.03 (0.76-1.38) 5 0.81 (0.26-2.55) 15 0.55(0.30-1.03)
<56 24 0.95 (0.60-1.48) 2 1.00 (0.21-4.82) 12 1.34 (0.69-2.62)
No. of additional prostate cancer cases
0 93 1.01 (0.76-1.35) 7 1.00 (0.35-2.85) 21 0.68 (0.39-1.18)
1 12 0.89 (0.49-1.63) 0 5 1.11 (0.43-2.85)
>2 2 1.37 (0.34-5.55) 0 --- 1 1.94 (0.26-14.20)
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Table 4. Poisson regression relative risks (RRs) and 95% confidence intervals (CIs) of cancer occurrence in first-degree relatives of sporadic, familial, and
hereditary prostate cancer probands versus first-degree relatives of the probands’ female companions*
Site
No. in 
control 
relatives
Sporadic! Familial}: Hereditary§
No. RR (95% Cl) No. RR (95% Cl) No. RR (95% Cl)
Breast 91 84 1.03 (0.77-1.39) 18 0.83 (0.50-1.38) 14 1.02 (0.58-1,79)
Colorectum 65 53 0.88 (0.61-1.27) 19 1.12(0.67-1.86) 11 1.30 (0.69-1.87)
Other digestive system 74 74 1.11 (0.80-1.53) 17 0.91 (0.54-1.55) 8 0.73 (0.34-1.59)
Bladder or kidney 17 19 1.23 (0.64-2.38) 5 1.15 (0.42-3.12) 2 1.07 (0.25-4.65)
Central nervous system 14 8 0.63 (0.26-1.50) 3 0.84 (0.24-2.93) 5 3.02 (1.08-8.41)
Head and neck 28 19 0.77 (0.43-1.39) 2 0.30 (0.07-1.24) 3 0.87 (0.27-2.88)
Hematopoietic system 27 29 1.21 (0.72-2.04) 9 1.35 (0.63-2.87) 3 0.91 (0.28-3.00)
Ovary 7 6 0.96 (0.32-2.85) 1 0.60 (0.07-4.85) 1 0.94 (0.12-7.68)
Endometrium 31 18 0.66 (0.37-1.17) 6 0.83 (0.35-1.99) 4 0.87 (0.31-2.46)
Other gynecologic system 20 7 0.41 (0.17-0.96) i 0.23 (0.03-1.70) 3 1.05 (0.31-3.52)
Respiratory system 68 47 0.77 (0.53-1.12) 12 0.70 (0.38-1.30) 11 1.45 (0.77-2.75)
Skin melanoma 76 76 1.11 (0.81-1.52) 20 1.04 (0.64-1.71) 7 0.74 (0.34-1.60)
Other 17 10 0.66 (0.30-1.44) 10 2.35 (1.08-5.14) 6 3.00 (1.18-7.63)
*RRs are adjusted for the effects of sex and age (>65 years versus <65 years).
t  Defined as simplex (single-case) families (n = 511).
tDefined as families that had a positive family history of prostate cancer but did not meet one of the three criteria of the hereditary group (n = 148).
§Defined as families that met one of the following criteria: 1) had a cluster of three or more relatives affected with prostate cancer within any nuclear family» such 
as a father and two sons affected or a group of three brothers affected; 2) prostate cancer occurred in each of three successive generations in either the probands’ 
paternal lineage or maternal lineage; or 3) had a cluster of two relatives, both affected with prostate cancer at 65 years of age or younger. These three criteria were 
based on the resulLs of a test of various models to explain familial clustering (n = 106 [includes 31 hereditary families identified in the current study plus 75 referred 
multiplex families]).
the risk of prostate cancer among male relatives. We found that 
the risk for prostate cancer is 76% higher among first-degree 
relatives of prostate cancer case patients compared with first-de­
gree relatives of control subjects. This higher risk does not seem 
to be modified by the presence of an additional breast cancer 
case in the nuclear family, but our study's power to detect statis­
tically significant differences in risk was fairly small. Further­
more, the risks for other tumor sites are not increased among 
relatives of prostate cancer patients. The absence of an increased 
risk for breast cancer, ovarian cancer, and endometrial cancer in 
so-called hereditary cancer families is especially worth noting. 
In fact, of the 690 prostate cancer families, only five had two 
breast cancer cases and one had three breast cancer cases in the 
nuclear family. There was only one family with two endometrial 
cancer cases in the nuclear family. Of these seven prostate can­
cer families, six were classified as sporadic, one as familial, and 
none as hereditary for prostate cancer. Although previous case- 
control studies demonstrated an association between breast can­
cer and prostate cancer using breast cancer probands, our study 
shows differing results using prostate cancer probands,
We did see, however, an increased risk for tumors of the 
central nervous system and other sites among the hereditary 
families (the group of other tumors mainly consists of ill- 
defined tumors of the musculoskeletal system, such as cancer of 
the hip and cancer of the back). This finding may reflect reality, 
but it may also be a chance finding due to small numbers. 
Another possible explanation is misclassification of tumor site. 
The interviewees may have remembered the site of distant 
metastases (brain or bone) in their relatives with cancer instead 
of the primary tumor site. In that case, the RRs for some of the 
primary sites listed in Table 4 will have been slightly underes­
timated.
All the analyses in this study were adjusted for age and sex. 
Data on other etiologic factors in relatives were not available for
our study. To minimize the number of strata in the analysis, age 
of relatives was dichotomized into two strata, younger than 65 
years of age and 65 years of age and older. Because age repre­
sents a very strong risk factor for all cancers, we checked for the 
existence of residual confounding by performing a reanalysis in 
which age was categorized into more strata. Results of this 
analysis were essentially unchanged.
By using Poisson regression analyses, we did not adjust for 
the inherent dependency of the data within each pedigree. Al­
though the estimated RRs should not be biased because of this 
dependency, their variances might have been slightly underes­
timated (i.e., the CIs may be too narrow). We have checked the 
degree of bias in the variances by reanalyzing familial clustering 
of prostate cancer and familial clustering of prostate cancer with 
breast cancer, using the computer program MULCOX2 (16). In 
this program, marginal distributions of multivariate failure times 
are formulated with Cox’s proportional hazards modeling (17) 
while leaving the nature of dependence among related failure 
time completely unspecified. The results of these analyses were 
identical to those we obtained with Poisson regression (both the 
point estimates and the CIs). Because in these Cox analyses age 
(of relatives) is used as the time scale, we obtained additional 
evidence of the absence of confounding by age.
To increase the power to detect differences in the risks of can­
cer among relatives of sporadic, familial, and hereditary prostate 
cancer case patients, we enriched the hereditary families with 75 
additional multiplex families. These multiplex families com­
prised a highly select group, and the data on cancer occurrence 
in these families were collected outside the context of the case- 
control study. Therefore, we performed an additional analysis 
on these multiplex families only to check the validity of our 
results. We compared the observed number of selected tumor 
sites with the expected numbers on the basis of general popula­
tion incidence data and person-years at risk. For the population
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incidence data, we extracted the age-specific, sex-specific, and 
calendar-year-specific incidence rates from the United States 
Data Registry program, version 58a (75). These data represent 
the incidence rates from the Connecticut Cancer Registry from 
1925 to 1975. We updated the rates to 1987, using volume 5 and 
volume 6 of Cancer Incidence in Five Continents (19,20). CIs 
of the observed/expected ratios were calculated using Byar’s ap­
proximation of the exact Poisson test (21).
In total, 48 cancers were observed among the first-degree 
relatives (offspring included) of the 75 probands, where 49.5 
were expected (RR = 0.97; 95% Cl = 0.71-1.29). The ob­
served/expected ratios for specific sites were as follows: 
colorectal cancer—RR = 1,06; 95% Cl = 0.48-2.01, respiratory 
tract cancer—RR = 1.61; 95% Cl = 0.73-3.05, breast cancer— 
RR = 0.96; 95% Cl = 0.44-1.82, endometrial cancer—RR =
0.45; 95% Cl = 0.01-2.53, and ovarian cancer—RR = 1.25; 95% 
Cl = 0.14-4.51.
Thus, even among families that were highly selected because 
of the presence of prostate cancer, the risks for cancer at other 
sites appeared not to be increased. This finding means that 
hereditary prostate cancer appears to be relatively site-specific 
and that it does not seem to be part of another hereditary cancer 
syndrome. Identification of a gene or genes through ongoing 
and future linkage analyses should provide a better under­
standing of the more common hereditary cancers such as pros­
tate cancer.
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